Subscribe today to receive notice of our latest thought leadership, articles, blogs and updates.
Insights
Open conversations, knowledge sharing, and fresh ideas promote positive change and transparency
Our latest blog posts, articles and podcasts
Sharing information with the industry is an important part of our mission. Our subject matter experts translate today’s news into comprehensive informational pieces to help you better understand the impact of a recent industry update, trend, or issue.
|
September 15, 2023 · Clinical Team
According to the U.S. Food and Drug Administration (FDA), Duexis — a single-tablet combination product containing ibuprofen, a nonsteroidal anti‐inflammatory drug (NSAID), and famotidine, a histamine H2–receptor blocker — will no longer be manufactured. Read more... |
|
September 13, 2023 · Public Policy & Regulatory Affairs Team
Read more... |
|
|
September 01, 2023 · Clinical Team
Earlier this year, the American Geriatrics Society (AGS) published an update to the AGS Beers Criteria® for potentially inappropriate medication (PIM) use in older adults (65 years of age and older). Older adults are more likely to experience unwanted adverse effects and be more sensitive to certain medications. Read more... |
|
|
August 16, 2023 · Public Policy & Regulatory Affairs Team
Brief postings include proposed updates to California DWC medical treatment guidelines and the Michigan Supreme Court rules on retro-applicability of certain auto no-fault fee schedule provisions. Read more... |
Page 7 of 7